Get started

Breakoutstocks

ALLCARGO Logistics are Stablishing and Sustaining in PerformanceNSE:ALLCARGO ................................................................................................................................................................................................................................................................................................................................................... KEY BUSSINESS HIGHLIGHTS Global events coupled with high demand across trade lanes during the second quarter of 2024 (calendar year) has led toimproved volumes and increased freight rates. Demand is expected to continue through the peak season till end of theyear. LCL volume for the quarter ended June’24 stood at 2.25 million CBM, similar on YoY basis and representing a QoQ growth of6%. FCL volume for the quarter stood at 156K TEUs, similar to last quarter and up 9% on a YoY basis. ECU Worldwide onboarded a new leadership team in Argentina, Uruguay and Paraguay as part of growth initiatives in LatinAmerica. Contract Logistics business has reported a revenue growth of 13% on a QoQ basis and 22% on a YoY basis on the back ofincreased wallet share from existing clients. Express Business: Operating cost continues to get optimized to bring about future growth in EBITDA. For Q1FY25 EBITDAstood at Rs. 20 crores, up 11% YoY and 33% on QoQ basis ................................................................................................................................................................................................................................................................................................................................................... Supply chain market is estimated to be at ₹63,000 crores. • ASCPL is a leading pan india 3PL player with an expansive network • Market leadership in chemical warehousing and dominance in western India • Building strengths in auto & engineering and ecommerce ...................................................................................................................................................................................................................................................................................................................................................
NSE:ALLCARGOLong
by iism-ExpertTrading
SEQUENT SCIENTIFIC - Multi Year Breakout StockINVERSE HEAD & SHOULDER PATTERN BREAKOUT STOCK FOR SWING TRADING > 2 Years of Inverse head & shoulder breakout BUY PRICE : 155 SL : 125 (only for swing traders) TARGET : 202, 250, 305 (100%) Disclaimer - All information on this page is for educational purposes only, we are not SEBI Registered, Please consult a SEBI registered financial advisor for your financial matters before investing And taking any decision. We are not responsible for any profit/loss you made.
NSE:SEQUENTLong
by Jagadheesh_JP
Natco Pharma Breakout Retest! 🚀 Hey Dosto! 👋 🔍 Chart Analysis: Natco Pharma - CMP 980 📊 🚀 Reasons for Trade: Strong Uptrend Cup and Handle Breakout Retest 💹 Trade Details: CMP: 980 SL: 918 Targets: 1090, 1188 🌟 Why Natco Pharma? After a cup and handle breakout, Natco Pharma has retraced for a retest, indicating potential upward momentum. 💡 Trade Strategy: 📈 Enter after retest confirmation. ⚖️ Set SL at 918. 🎯 Targets at 1050, 1110, and 1200. 📈 Disclaimer: I'm not a SEBI registered analyst. Trade at your own discretion. 🚀 Excited about this trade? Share your thoughts below! Let's discuss! 🤝💬 #NatcoPharma #StockMarket #TradeAlert #TechnicalAnalysis #BreakoutRetest 📈✨
NSE:NATCOPHARM
by satyam15
ALKYLAMINE is Reacting & Showing Change in Structure & STORYNSE:ALKYLAMINE ............................................................................................................................................................................................................................................ TURN-AROUND STORY IS IN PROGRES IN TERMS OF PRODUCTION FACILITY AND SUSTAINABLE PRODUCT WHICH WILL BE ABLE COMPETE CHINESE COMPATETORS ............................................................................................................................................................................................................................................ Company has reduced debt. Company is almost debt free. Company has a good return on equity (ROE) track record: 3 Years ROE 19.0%. Company has been maintaining a healthy dividend payout of 26.5%. ............................................................................................................................................................................................................................................ Strong financial risk profile and ample liquidity: Networth was healthy at Rs. 1263 crores as on March 31, 2024 (Rs 1165 crore as on March 31, 2023), with nil gearing as on March 31, 2024.The total outside liabilities to adjusted networth (TOL/ANW) ratio though had decreased to 0.25 time as on March 31, 2024 from 0.36 times as on March 31, 2023, and it is expected to improve over the medium term driven by steady accretion to reserves, absence of long term loans and moderate reliance on external debt for working capital and capex. Cash and cash equivalents of Rs 17 crore as on March 31, 2024, provide cushion to overall liquidity. Interest coverage ratio has improved to 60.4 times March 31, 2024. It is expected to remain healthy over the medium term. ............................................................................................................................................................................................................................................
NSE:ALKYLAMINELong
by iism-ExpertTrading
KOPRAN Showed Breakout with Huge Volume at 52 Weeks High ZoneNSE:KOPRAN The co. has set up a new API plant at Panoli, commercial production at this facility is expected to be started from Q3 FY25. In FY23, it completed upgradation and expansion of the multi-product plant at the Mahad facility for existing products and to manufacture new molecules. An integrated Pharmaceutical Company, committed to supplying International Quality Formulations and Active Pharmaceutical Ingredients (APIs) globally. State-of-the-art manufacturing facilities and products with various accreditations and approvals by major global regulatory authorities. The formulations vertical is operated through Kopran Limited. The API vertical is being operated under Kopran Research Laboratories Ltd. (KRLL), a wholly owned subsidiary of Kopran Limited
NSE:KOPRANLong
by iism-ExpertTrading
GENUSPOWER- Bullish Breakout and Strong Volume Support Bullish Breakout Above Resistance: The stock has broken above a significant resistance level at ₹389.10, indicating a bullish trend. Range Trading Since July: The stock had been trading within a range from July, between ₹343.70 and ₹389.10, before the breakout. Strong Volume Support: The recent breakout is supported by good volume, adding strength to the bullish move. Positive RSI: The Relative Strength Index (RSI) is above 50, suggesting continued momentum in the upward direction.
NSE:GENUSPOWERLong
by GlobalMarketGuru